PharmacoEconomics

, Volume 27, Issue 5, pp 435–438 | Cite as

Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs

  • Brian Godman
  • Ulrich Schwabe
  • Gisbert Selke
  • Björn Wettermark
Research Letter

References

  1. 1.
    Godman B, Bucsics A, Burkhardt T, et al. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev Pharmacoeconomcis Outcomes Res 2008; 8: 357–71CrossRefGoogle Scholar
  2. 2.
    Wettermark B, Godman B, Andersson K, et al. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics 2008; 26: 537–50PubMedCrossRefGoogle Scholar
  3. 3.
    Godman B, Haycox A, Schwabe U, et al. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 2008; 26:91–8PubMedCrossRefGoogle Scholar
  4. 4.
    Godman B, Wettermark B, Hoffman M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoeconomcis Outcomes Res 2009; 9: 65–83CrossRefGoogle Scholar
  5. 5.
    Beishon J, McBride T. Scharaschkin S. et al. National Audit Office. Prescribing costs in primary care. 14 May 2007 [online]. Available from URL: http://www.nao.org.uk [Accessed 2007 May 21]
  6. 6.
    Simoens S. Trends in generic prescribing and dispensing in Europe. Expert Rev Clin Pharmacol 2008; 1: 497–503CrossRefGoogle Scholar
  7. 7.
    Grandfils N, Sermet C. Pharmaceutical policy in France: a mosaic of reforms. Eurohealth 2006; 12: 15–7Google Scholar
  8. 8.
    van Ganse E, Chambea G, Becquart B. et al. France: pharmaceutical pricing and reimbursement information, October 2007 [online]. Available from URL: http://ppri.oebig.at/Downloads/Results/France_PPRI_2007.pdf [Accessed 2008 Sep 20]
  9. 9.
    Paris V. Pharmaceutical regulation in France 1980–2003. Int J Health Plann Manage 2005; 20: 307–28PubMedCrossRefGoogle Scholar
  10. 10.
    Kanavos P. Generic policies: rhetoric vs reality. Euro Observer 2008; 10: 1–6Google Scholar
  11. 11.
    Seeley E, Kanavos P. Generic medicines from a societal perspective: savings for healthcare systems? Eurohealth 2008; 14: 18–22Google Scholar
  12. 12.
    Perry G. The European generic pharmaceutical market in review: 2006 and beyond. J Generic Med 2006; 4: 4–14CrossRefGoogle Scholar
  13. 13.
    Dolezal T. Practical application of PE and HTA in Czech Republic November 2008 [online]. Available from URL: http://www.ceestahc.org/pliki/symp2008/dolezal.pdf [Accessed 2009 Feb 16]
  14. 14.
    Busse R, Schreyögg J, Henke KD. Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures? Int J Health Plann Manage 2005; 20: 329–49PubMedCrossRefGoogle Scholar
  15. 15.
    Guidelines for ATC classification and DDD assignment 2006. Oslo: WHO Collaborating Centre for Drug Statistics Methodology [online]. Available from URL: http://www.whocc.no [Accessed 2009 Apr 9]
  16. 16.
    Arzneiverordnungs Report 1999 to 2008. Springer Medizin Verlag Heildelberg [online]. Available from URL: http://www.springer.com/pharma/book/978-3-540-69218-8 [Accessed 2009 Jan 19]
  17. 17.
    Wessling A, Lundin D. The review of drugs against disease caused by acid stomach: a summary. Solna: Pharmaceuticals Benefits Board, 2006 [online]. Available from URL: http://www.tlv.se/upload/genomgangen/summary-stomach-acid.pdf [Accessed 2009 Mar 6]
  18. 18.
    Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 2008; 336: 2–3PubMedCrossRefGoogle Scholar
  19. 19.
    Björnsson E, Abrahssom H, Simrén M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006; 24: 945–54PubMedCrossRefGoogle Scholar
  20. 20.
    Yang YY, Lewis J, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296 (24): 2947–53PubMedCrossRefGoogle Scholar
  21. 21.
    Walley T, Folino-Gallo P, Schwabe U, et al., on behalf of the EuroMedStat Group. Variations and increase in use of statins across Europe: data from administrative databases. BMJ 2004; 328: 385–6PubMedCrossRefGoogle Scholar
  22. 22.
    Pfizer criticises SORTIS reference prices: Ministry of Health recommends change. Handelsblatt 2004 Nov 8 [online]. Available from URL: http:www.handelsblatt.com/archive/pfizer-kritisiert-sortis-festbetrag-ministerium-raet-zum-wechsel;816275 [Accessed 2009 Jan 19]
  23. 23.
    Kastelein J, Akdim F, Stroes E, et al. Simvastatin with or without ezetimibe in familial hypercholesterolaemia. N Engl J Med 2008; 358 (14): 1431–43PubMedCrossRefGoogle Scholar
  24. 24.
    Brown GB, Taylor A. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 2008; 358 (14): 1504–7PubMedCrossRefGoogle Scholar
  25. 25.
    Alonso PW. Vytorin support statement raises questions over American Heart Association funding. 2008 Jan 24 [online]. Available from URL: http://www.yourlawyer.com/articles/read/13745 [Accessed 2009 May 9]
  26. 26.
    Saul S. Heart group backs drug made by Ally. New York Times 2008 Jan 24 [online]. Available from URL: http://www.nytimes.com/2008/01/24/business/24heart.html?_r=1 [Accessed 2009 May 9]
  27. 27.
    Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359 (13): 1343–56PubMedCrossRefGoogle Scholar
  28. 28.
    Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008; 359 (13): 1357–66PubMedCrossRefGoogle Scholar
  29. 29.
    Alsheikh-Ali A, Karas R. Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: a post-marketing analysis. Jn Clinical Lipidology 2009; 3 (2): 138–42CrossRefGoogle Scholar
  30. 30.
    Jack A. Balancing big pharma’s books. BMJ 2008; 336: 418–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Brian Godman
    • 1
    • 2
  • Ulrich Schwabe
    • 3
  • Gisbert Selke
    • 4
  • Björn Wettermark
    • 5
    • 6
  1. 1.Institute for Pharmacological Research ‘Mario Negri’MilanItaly
  2. 2.Prescribing Research GroupUniversity of Liverpool Management SchoolLiverpoolUK
  3. 3.Institute of PharmacologyRuprecht-Karls University HeidelbergHeidelbergGermany
  4. 4.AOK Research InstituteBerlinGermany
  5. 5.Regional Drug Experts LÄKSAK, Department of Drug Management and InformaticsStockholm County CouncilStockholmSweden
  6. 6.Department of Laboratory Medicine, Division of Clinical Pharmacology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services, Karolinska InstitutetKarolinska University Hospital HuddingeStockholmSweden

Personalised recommendations